About Edge Therapeutics

Edge Therapeutics, Inc. is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening neurological conditions. Our product candidates utilize our proprietary Precisa development platform, which allows us to create therapeutics that are based on specific physical and chemical properties that enable targeted delivery to the exact site of the injury, and provide a controlled and sustained drug release to the affected area. The Precisa platform also allows Edge to advance new product candidates from concept to preclinical testing in an expedited manner.

“At Edge, our primary goal is to save lives around the world by developing therapies for serious, unmet medical conditions in the hospital setting. This purpose drives our strategy and our work each and every day.”
Brian Leuthner
President and CEO

Latest News

Edge Therapeutics enrolls first patient in Phase 1/2 of NEWTON Study of EG-1962
for improvement of patient outcome after Aneurysmal Subarachnoid Hemorrhage, a potentially life-threatening condition.

Read More

 

Precisa Platform

Precisa, our proprietary, programmable, biodegradable polymer-based development platform, enables creation of polymer-based therapeutics capable of delivering directly to the site of injury.

Read More

 

EG-1962™

Our lead product candidate, EG-1962, is a polymer-based microparticle containing nimodipine developed with the Precisa platform to improve patient outcomes after Aneurysmal Subarachnoid Hemorrhage.

Read More